Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs
Back to article page
|Updated:2021-08-27
|
Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs
Chinese Journal of Integrative MedicineVol. 15, Issue 2, Pages: 145-148(2009)
Affiliations:
Department of Hematology, First Clinical Medical College Affiliated to Zhejiang University of Traditional Chinese Medicine,Hangzhou,China
Author bio:
Funds:
Supported by the Key Program of the Governmental Office of Sciences and Technology of Zhejiang Provincial (No. 2006c23039)
Zheng, Br., Shen, Jp., Zhuang, Hf. et al. Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs., Chin. J. Integr. Med. 15, 145–148 (2009). https://doi.org/10.1007/s11655-009-0141-9
Bing-rong Zheng, Jian-ping Shen, Hai-feng Zhuang, et al. Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs. [J]. Chinese Journal of Integrative Medicine 15(2):145-148(2009)
Zheng, Br., Shen, Jp., Zhuang, Hf. et al. Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs., Chin. J. Integr. Med. 15, 145–148 (2009). https://doi.org/10.1007/s11655-009-0141-9DOI:
Bing-rong Zheng, Jian-ping Shen, Hai-feng Zhuang, et al. Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs. [J]. Chinese Journal of Integrative Medicine 15(2):145-148(2009) DOI: 10.1007/s11655-009-0141-9.
Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs
摘要
To study the therapeutic effect of combined therapy with Chinese drugs and immuno-suppressors
the efficacy associated factors and adverse effects as well. A retrospective analysis was conducted on 65 patients with SAA treated by combined therapy which was supplemented with cyclosporin A
androgen
hematopoietic growth factor
etc. Of the 57 patients followed-up
26 (45.6%) were basically cured
15 (26.3%) remitted
and 8 (14.0%) improved markedly
the total effective rate being 85.9%. By separately comparing with a single item of clinical data
it was shown that the therapeutic effectiveness was correlated
to a certain extent
with age
illness duration
neutrophil count
and bone marrow proliferation in patients before treatment
as well as with infection that occurred in the follow-up period. It was obviously higher in patients with peripheral neutrophil count > 0.5 × 10 109/L (P<0.05). Various degrees of serum sickness-like reactions occurred in the treatment of 36 patients
including fever in 36 (63.2%)
skin rash in 8 (14.0%)
and musculoskeletal pain in 5 (8.8%). The therapeutic effect of combined therapy with Chinese drugs and ALG/ATG in treating SAA could be affirmed
showing some superiority as compared with Western medicine alone. The patients’ age
duration of illness
neutrophil count
and bone marrow proliferation before treatment
and degree of infection that occurred could affect the therapeutic efficacy to a certain extent. Adverse reactions resulting from the combined therapy are less
showing the toxicity reducing and effect enhancing action of Chinese drugs.
Abstract
To study the therapeutic effect of combined therapy with Chinese drugs and immuno-suppressors
the efficacy associated factors and adverse effects as well. A retrospective analysis was conducted on 65 patients with SAA treated by combined therapy which was supplemented with cyclosporin A
androgen
hematopoietic growth factor
etc. Of the 57 patients followed-up
26 (45.6%) were basically cured
15 (26.3%) remitted
and 8 (14.0%) improved markedly
the total effective rate being 85.9%. By separately comparing with a single item of clinical data
it was shown that the therapeutic effectiveness was correlated
to a certain extent
with age
illness duration
neutrophil count
and bone marrow proliferation in patients before treatment
as well as with infection that occurred in the follow-up period. It was obviously higher in patients with peripheral neutrophil count > 0.5 × 10 109/L (P<0.05). Various degrees of serum sickness-like reactions occurred in the treatment of 36 patients
including fever in 36 (63.2%)
skin rash in 8 (14.0%)
and musculoskeletal pain in 5 (8.8%). The therapeutic effect of combined therapy with Chinese drugs and ALG/ATG in treating SAA could be affirmed
showing some superiority as compared with Western medicine alone. The patients’ age
duration of illness
neutrophil count
and bone marrow proliferation before treatment
and degree of infection that occurred could affect the therapeutic efficacy to a certain extent. Adverse reactions resulting from the combined therapy are less
showing the toxicity reducing and effect enhancing action of Chinese drugs.
He GS, Shao ZH. Current situation of immune inhibitory treatment on aplastic anemia. Chin J Hematol (Chin) 2002;23:611–613.
Chu YL, Hao YS, Bian SK. Clinical study of antithymocyte globulin in the treatment of children aplastic anemia. Chin J Hematol (Chin) 1986;7:198.
Zhang ZN, ed. Norm for diagnosis and efficacy assessment of hematopathy. Beijing: Science Press; 2008:19–23.
Ying XM, Wang YP. Adverse reaction of antithymocyte globulin in the treatment of 28 cases children aplastic anemia. J China Pediatr Blood (Chin) 2000;5:198–201.
Yu F, Tang SQ, Wang JW. Therapeutic effect of antithymocyte/antilymphocyte globulin on severe aplastic anemia and therapy-related complications. Chin J Contemporary Pediatr (Chin) 2006;8:479–481.
Bacigalupo A, Brand R, Oneto R, Oneto R, Bruno B, Socie G, Passweg J, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy-The European Group for Blood and Marrow Transplantation Experience. Semin Hematol 2000;37:69–80.
Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000;95:1931–1934.
Rosenfeld S, Follmann D, Nunezo, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003;289:1130–1135.
Shao ZH, Yuan Y. Immune pathogenesis and therapy for aplastic anemia. Chin J Pract Intern Med (Chin) 2006;26:252–255.
Bone marrow angiogenesis in patients presenting with differential Chinese medicine syndrome: Correlation with the clinico-pathological features of aplastic anemia
Effect of Chinese drugs combining with chemotherapy on quality of life in 146 children with solid tumor
Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China
Clinical efficacy and safety of Gubitong Recipe (骨痹通方) in treating osteoarthritis of knee joint
Current status and progress of study on perioperative period
Related Author
No data
Related Institution
Department of Hematology, the First Affi liated Hospital, Zhejiang University of Traditional Chinese Medicine
Beijing Children’s Hospital Affiliated to the Capital Medical University
Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences
Traditional Chinese Medicine Department of Rheumatism, China-Japan Friendship Hospital
Department of Surgery, Dongzhimen Hospital of Beijing, University of Chinese Medicine